Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of apatinib combined with XELOX as neoadjuvant treatment for locally advanced gastric cancer
ChiCTR1800017323Phase 4Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jul 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib, capecitabine and oxaliplatin in gastric cancer (GC) and gastric adenocarcinoma, sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Pathological response rate, R0 resection rate and 7 more. Started Jul 2018; status: recruiting.
02
Drugs
Rivoceranibcapecitabineoxaliplatin
03
Conditions
gastric cancer (GC)gastric adenocarcinoma
Beyond the preview
Go deeper on ChiCTR1800017323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017323.